Non-small-cell lung cancer (NSCLC) represents the most frequent and therapy-refractive sub-class of lung cancer. Improving apoptosis induction in NSCLC represents a logical way forward in treating this tumor. Cisplatin, a commonly used therapeutic agent in NSCLC, induces activation of N-terminal-c-Jun kinase (JNK) that, in turn, mediates induction of apoptosis. In analysing surgical tissue samples of NSCLC, we found that expression of MKP1/CL100, a negative regulator of JNK, showed a strong nuclear staining for tumor cells, whereas, in normal bronchial epithelia, MKP1 was localized in the cytoplasm as well as in nuclei. In the NSCLC-derived cell lines H-460 and H-23, we found that MKP1 was constitutively expressed. Expressing a small-interfering RNA (siRNA) vector for MKP1 in H-460 cells resulted in a more efficient activation by cisplatin of JNK and p38 than in the parental cells, and this correlated with a 10-fold increase in sensitivity to cisplatin. A similar response was also observed in H-460 and H-23 cells when treated with the MKP1 expression inhibitor RO-31-8220. Moreover, expression of a siRNA-MKP2, an MKP1-related phosphatase, had no effect on H-460 cell viability response to cisplatin. Tumors induced by H-460 cells expressing MKP1 siRNA grew slower in nu À /nu À mice and showed more susceptibility to cisplatin than parental cells, and resulted in an impaired growth of the tumor in mice. On the other hand, overexpression of MKP1 in the H-1299 NSCLC-derived cell line resulted in further resistance to cisplatin. Overall, the results showed that inhibition of MKP1 expression contributes to a slow down in cell growth in mice and an increase of cisplatin-induced cell death in NSCLC. As such, MKP1 can be an attractive target in sensitizing cells to cisplatin to increase the effectiveness of the drug in treating NSCLC.
Introduction
Lung cancer is the leading cause of cancer-related death in Western countries. This invariably results, secondarily, from being diagnosed at a highly disseminated stage when therapeutic options are rarely curative. Currently, most therapies for disseminated lung cancer are centered on chemotherapy with drugs such as cisplatin, docetaxel, vinorelbine and gemcitabine. Drug resistance and the patient's poor performance status (apart from the late stage of diagnosis) are jointly responsible for a median survival time of approximately 1 year from the time of diagnosis. This low survival rate reflects, in part, the ability of tumor cells to maintain survival pathways during malignancy progression (Vivanco and Sawyers, 2002; Perona and Sa´nchez-Pe´rez, 2004 ) despite the therapy.
Conversely, chemotherapy agents activate signaling pathways that can be induced in response to mitogen stimulation and which, frequently, are deregulated in the tumor as part of the progression-transformation in the cell. As a consequence of these processes, the effectiveness of chemotherapy is a balance between pro-and antiapoptotic signals elicited by the treatment and those that are upregulated in the tumor. As mentioned above, chemotherapy administered to non-small-cell lung cancer (NSCLC) patients with non-resectable tumor at stages III and IV is, usually, a platinum-based combination regimen, in which the platinum compound is cisplatin. The drug (cis-diaminedichloroplatinum; c-DDP, cisplatin) is a DNA-reactive agent that induces lesions in DNA that include intra-strand 1,2-d(GpG), 1,2-d(ApG) and 1,3-d(GpNpG) and inter-strand crosslinking (Eastman, 1985) . Like many anticancer agents, cisplatin induces a sustained activation of the mitogenactivated protein (MAP) kinases, N-terminal-c-Jun kinase (JNK) and p38 (Sa´nchez-Pe´rez et al., 2000) . Each MAP kinase sub-family is activated by a specific upstream MAP kinase kinase, which phosphorylates threonine as well as tyrosine residues within a conserved T-X-Y motif (Hibi et al., 1993; De´rijard et al., 1994; Kyriakis et al., 1994) . These residues are dephosphorylated by dual-specific protein phosphatases, resulting in the inactivation of MAP kinases (Keyse, 1995) . The activation of the MAP kinase family members leads to the phosphorylation of numerous cellular effectors, including protein kinases such as MAPKAPK1, MAP-KAPK2/3 and Mnk1/2 and transcription factors such as c-jun, ATF-2, MEF2c and CHOP, which, ultimately, are responsible for the fate of the cell (Alpert et al., 1999) . The activation of JNK by cisplatin takes place via the MEKK1/SEK1 cascade and is directly related to cell death (Sa´nchez-Pe´rez and Perona, 1999) . Dephosphorylation and inactivation of JNK by the dual-specific phosphatases CL100 and hVH5 result in protection against cisplatin-induced apoptosis (Sa´nchez-Pe´rez et al., 2000) . Further, both phosphatases are able to inhibit transcriptional activation of c-Jun, the principal physiological substrate of JNK (Kyriakis et al., 1994) . We have shown previously (Sa´nchez-Pe´rez and Perona, 1999 ) that c-jun is necessary for the induction of apoptosis in response to cisplatin in a cell line derived from c-jun knockout mice and which appears to be more resistant than normal cells to cisplatin-induced cell death. This effect is specific to c-jun as transfection of cjun into the c-jun À/À cell line restores its endogenous activity, and which results in a phenotype similar to that of parental (wild-type (wt)) cells. The role of c-jun in apoptosis has been described in other cell lines, such as PC12 cells, which undergo apoptosis following NGF withdrawal in a c-jun-dependent manner (Ham et al., 1995) . In agreement with these results, constitutive expression of c-jun in NIH3T3 cells induces apoptosis upon serum deprivation (Ham et al., 1995; Bossy et al., 1997) .
MKP1/CL100 is an immediate-early gene whose expression is regulated by mitogenic, inflammatory and DNA-damage stimuli (Beltman et al., 1996; Sa´nchez-Pe´rez et al., 1998; Li et al., 2001) . Although MKP1 levels in normal cells are low, increased levels of MKP1 have been found in human ovarian carcinoma, breast and prostate cancer (Srikanth et al., 1999; Denkert et al., 2002; Wang et al., 2003) . In this report, we have investigated the expression and function of MKP1 in the chemotherapy response to cisplatin in NSCLC. In surgical samples from patients with NSCLC, we observed that the expression in the tumor differs from normal epithelium. By using the NSCLCderived cell line H-460, which showed increased levels of MKP1, we inhibited MKP1 expression using small interfering RNA (siRNA) technology. We found that the resulting cells are 10-fold more sensitive to cisplatin, and that tumors induced by these cells, as well, were more sensitive to cisplatin than tumors from control cells, indicating that MKP1 plays a critical role in negative regulation of cisplatin-induced cell death in NSCLC.
Results

Expression of MKP1 in NSCLC biopsies
To check the frequency of expression of the MKP1 phosphatase in NSCLC, we evaluated expression in sections of tumor samples of 32 patients of NSCLC (Table 1) . Of the total, nearly 60% correspond to squamous cell carcinomas, 25% to adenocarcinomas and the rest to undifferentiated large-cell carcinomas. Briefly, half of the samples were grouped into stage IB, and the rest into stage IIB. We found that in tumor tissues, staining was mainly nuclear in nearly 80% of cases ( Figure 1 and Table 2 ). By contrast, stain was localized both in the cytoplasm and nuclei in normal MKP1 controls sensitivity to cisplatin in NSCLC S Chattopadhyay et al bronchial epithelium surrounding the tumor, showing weaker nuclear staining than in tumor tissue ( Figure 1) . All values were statistically significant. The results showed that this distribution of MKP1/CL100 expression in the cytoplasm and nuclei was homogeneously distributed among the different subgroups of patients. These results are in agreement with those observed by Vicent et al. (2004) , who also detected higher levels of MKP1 protein in NSCLC-derived cell lines. Our results suggested that nuclear expression of MKP1 could be an early event in the disease progression of NSCLC.
JNK and p38 signaling pathways are activated by cisplatin in H-460 cells In order to explore the physiological role of the high levels of MKP1 observed in the tumor samples, we commenced this investigation by analysing its possible role in chemotherapy responses. We decided to study the signaling pathways induced by cisplatin in H-460 cells, as we have previously identified MKP1 as an inhibitor of the cell death response to cisplatin. Cells were treated with cisplatin, and at different times the kinetic parameters for JNK and p38 activation were studied. JNK was activated in H-460 cells with a late-onset kinetic, and the activation persisted for at least up to 24 h (Figure 2a ), decreasing by 36 h. The kinetic parameters for p38 activation were very similar to that of JNK. We had previously found, in different cell systems, that the kinetic of activation of JNK was modulated by the dual phosphatase MKP1/CL100 (Sa´nchez-Pe´rez et al., 2000) . We subsequently investigated the expression levels of this protein in H-460 cells following the addition of cisplatin. We found that, as expected, H-460 cells constitutively expressed MKP1, and the expression decreased to undetectable levels within 24 h (Figure 2a ). This correlated well with the kinetics of activation of JNK and p38, which increase in the time the MKP1 levels are downmodulated. ERK activation upon cisplatin treatment varies from one cell type to another (Persons et al., 1999; Woessmann et al., 2002) . We found that in H-460 cells ERK1/2 was activated at a very late time (24-36 h), suggesting that this process is not dependent on the decrease in MKP1 levels. On the other hand, in order to verify that the late activation of JNK is specific to cisplatin activation, we irradiated H-460 cells with 40 J/m 2 of UVC and detected an early and transient activation of JNK and p38 (Figure 2b ), as described previously (Sa´nchez-Pe´rez et al., 1998).
Inhibition of MKP1/CL100 expression by siRNA sensitizes H-460 cells to cisplatin treatment We had reported previously (Sa´nchez-Pe´rez et al., 2000) that enforced expression of MKP1/CL100 in 293T cells protects against cisplatin-induced cell death. With this in mind, we checked whether the inhibition of MKP1 expression could improve cisplatin cytotoxicity responses in H-460 cells. We transfected H-460 cells with a siRNA expression vector for MKP1 and pSRMKP1RNAi, and selected a stable expression using puromycin resistance (H-460MKP1siRNA cells). Control cells were obtained by transfection with the pSuperRetro empty vector. We did not isolate individual clones of siRNA-expressing cells so as to pre-empt clone-related variations in the results. We observed that expression of this construct was able to attenuate MKP1 mRNA levels, monitored via reverse transcriptase (RT)-PCR ( Figure 3a) . When we assessed MKP1 protein levels by Western blotting (Figure 3b) , the results were very close to the ones obtained for the MKP1 mRNA levels. Finally, we studied MKP1 expression in H460MKP1siRNA cells by immunofluorescence ( Figure 3c ) and we observed a complete inhibition in MKP1 nuclear expression in a major proportion of H-460MKP1siRNA cells relative to control cells. As we had used a pool of stable clones, we were unable to obtain a complete inhibition in MKP1 mRNA or protein levels, but we were able to find cells using immunofluorescence that showed complete abrogation of MKP1 expression. We also obtained an MKP1 controls sensitivity to cisplatin in NSCLC S Chattopadhyay et al H-460-derived cell line expressing a GFPsiRNA, and no difference in MKP1 expression was found when compared to wtH-460 cells (data not shown). From all these findings, we concluded that the siRNA construct designed for MKP1 was able to knock-down the MKP1 expression successfully. We proceeded, subsequently, to investigate the activation of JNK as well as p38 kinase and PARP degradation (as a test for apoptosis) in H-460MKP1siR-NA cells. In H-460SuperRetro cells, caspase activation takes place around 20 h after cisplatin treatment, whereas in H-460MKP1siRNA, activation of caspase occurs already at 14 h ( Figure 4 ). Also, in these cells, activation of JNK starts at earlier times than in control cells, in fact, basal levels of JNK activation could be observed in H-460MKP1siRNA untreated cells. Similar results were observed for p38 activation. These results are consistent with those obtained in 293T cells expressing a dominant-negative form of MKP1, which were more sensitive for SAPK activation by cisplatin than the corresponding control cells (Sa´nchez-Pe´rez et al., 2000) . When we compared cell viability in response to cisplatin of H-460MKP1siRNA with their respective control cells, we found that H-460MKP1siR-NA cells were one order of magnitude more sensitive to cisplatin than their control H-460 cells (Figure 5a ). This observation indicated that the manipulation of MKP1 protein levels by RNA interference could, indeed, improve cisplatin responses in cells that overexpressed this protein, in agreement with the results obtained for PARP activation (Figure 4 ). We monitored cell viability, by a clonogenic assay, of surviving cells to cisplatin in H-460MKP1siRNA and control cells, as well ( Figure 5b ). We obtained a decrease of 40% in cell survival in H-460MKP1siRNA cells treated with cisplatin, relative to the controls. This was in agreement with the cell viability estimations, obtained above.
As we observed such a difference in sensitivity to cisplatin of H-460MKP1siRNA cells, we checked if these differences were due to alteration in the growth kinetics of MKP1 controls sensitivity to cisplatin in NSCLC S Chattopadhyay et al these cells due to the RNA interference vector expression. Both, control-and siRNA-transfected H-460 cells grew at comparable rates when cultured in vitro (Figure 5c ). In order to check if the sensitization of H460MKP1siRNA cells was an event linked to this cell line and also if an alternative method for manipulating MKP1 levels would have the same effect, we used both H-460 and H-23 cell lines, the latter also expressing high basal levels of MKP1 (Vicent et al., 2004) . Treatment of both cell lines with the inhibitor of MKP1 expression RO-31-8220 (Beltman et al., 1996) resulted, with a different timing, in a reduction in MKP1 expression to almost undetectable levels ( Figure 6a ). H-460 cells treated for 1 h with RO-31-8220 showed an earlier (from 9 to 3 h) and more intense activation of JNK and also p38 than untreated cells (Figure 6b) . In H-23, cells treated for 6 h with RO-31-8220 also showed an earlier activation of both JNK and p38 kinases ( Figure 6c ). As R031-8220 was also described as a PKC inhibitor, we assayed the effect of another PKC inhibitor, GO6976, on JNK activation by cisplatin and observed no effect on JNK activation, in agreement with the results of other groups (data not shown) (Standaert et al., 1999 ). The treatment of both H-460 and H-23 cells with RO-31-8220 and cisplatin was able to sensitize these cells to cisplatin when compared to control cells (Figure 7 ), indicating that inhibition of MKP1 expression, by either RNAi or by chemical inhibitors, was a valid strategy to sensitize NSCLC cells to cisplatin. These results are also supported by the observation that MKP1-deficient MEFs are more sensitive to anysomicin-induced apoptosis (Wu and Bennett, 2005) , further emphasizing the importance of MKP1 in regulating stress-induced cell death.
We have previously published that enforced expression of MKP1 was able to induce survival capacity to cisplatin treatment (Sa´nchez-Pe´rez et al., 2000) . To prove this in NSCLC, we constitutively expressed MKP1 in the H1299 cell line (that does not express either MKP1 or MKP2) either alone or in combination with the pSRMKP1RNAi vector. As expected, H1299MKP1 cells expressed the myc-tagged MKP1 protein and the levels were strongly reduced in H1299MKP1 cells also transfected with the pSRMKP1RNAi vector (H1299MKP1-MKP1siRNA) (Figure 8a ). We then studied the survival capacity to cisplatin treatment and found that H1299 cells expressing MKP1 were more resistant to cisplatin than parental cells (Figure 8b ). Furthermore, H1299 cells expressing both MKP1 and MKP1siRNA behave like the parental cells, indicating again that the expression of MKP1 protects NSCLC cells against cisplatin treatment.
Knock down of MKP2 expression did not influence cell viability response to cisplatin MKP1/CL100 is a member of a dual phosphatase family of proteins. Among the family members, MKP2 showed a 60% sequence homology to MKP1, and also similar substrate specificity (Hirsch and Stork, 1997) . To verify that the results obtained in H-460MKP1siRNA cells were specific for the downregulation of MKP1 expression, we generated an H1299 cell line overexpressing MKP2. H1299MKP2 cells expressed the myc-tagged MKP2 protein (Figure 9a) , and when we studied the survival capacity to cisplatin, we observed almost no differences with the control cells (Figure 9b) . We also obtained a siRNA expression vector for MKP2 and stably transfected it in H-460 cells to monitor the decrease in MKP2 protein levels using Western blotting MKP1 controls sensitivity to cisplatin in NSCLC S Chattopadhyay et al ( Figure 10a ). No differences were observed in viability response to cisplatin in H-460MKP2siRNA cells when compared with control cells treated with cisplatin ( Figure 10b ). These findings indicated that the results obtained in H-460MKP1siRNA cells were specifically related to the inhibition in MKP1 expression by the siRNA vector, and that MKP1/CL100 is the relevant enzyme controlling sensitivity to cisplatin in H-460 cells.
H-460MKP1siRNA-induced tumors grow slower and are more sensitive to cisplatin We inoculated H-460 control and H-460MKP1siRNA cells in nu À /nu À mice and studied the influence of the lack of expression of MKP1 on tumorigenicity as well as response to cisplatin. Both cell lines were inoculated in nude mice, and after 14 days when tumor development was observed, cisplatin was administered at 5 mg/kg body weight to half of each group of animals every other day for a total of five administrations. Tumor measurements were performed on the first day of cisplatin injection, and the increase in volume size monitored from the day of the injection. The results obtained showed clearly (Figure 11a and c) that, firstly, tumors induced by H-460MKP1siRNA cells grow more slowly than H-460 control tumors. The expression of MKP1 was verified both in control cells-induced tumors and in H-460MKP1siRNA tumors (Figure 11b ), indicating the functionality of the SiRNA vector in cells injected in the mice. In agreement with the results observed in tumor growth, a slower growth of MKP1-deficient MEFs has also been reported (Wu and Bennett, 2005) . Both cases are not in complete agreement with our results obtained in vitro, which had shown both cell lines (H-460 and H460MKP1siRNA) having a similar overall growth kinetic. This suggests that in lung cancer, the tumor environmental conditions are less favorable for H460siRNA cells. Secondly, despite H-460MKP1siRNA tumors growing more slowly than H-460 tumors, they were more sensitive to cisplatin treatment than H-460-induced control tumors, which supports the results obtained in vitro. The ratio of tumor growth among H-460 tumors when treated with cisplatin was 1.68, whereas it was 3.77 for H-460siRNA tumors. All these data were statistically significant. This implies that these tumors responded much more efficiently to cisplatin Both cell lines were seeded in 24-well plates and, when indicated, pretreated for 1 and 6 h, respectively, with RO-31-8220, and cisplatin was added the following day at concentrations ranging from 0 to 10 mg/ml. After 48 h, the cells were fixed with glutaraldehyde, stained with crystal violet and the percentage staining calculated according to standard procedures. Data represent the means of two experiments performed in quadruplicate.
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Discussion
Chemotherapy is one of the strategies most widely used in the treatment of cancer. Often, however, the tumors do not succumb to the drugs. This problem is especially important in the treatment of NSCLC. Lung cancer is a major cause of cancer mortality, and accounts for about 20% of all cancer deaths worldwide. Many genetic alterations are associated with development of this type of tumor (Slebos and Rodenhuis, 1989; Levin et al., 1994; Wiest et al., 1997) . Some of them, such as the RAS mutations or overexpression, or mutations in growth factor receptors, are also related to an increased survival of tumor cells, when confronted with chemotherapy (Kim et al., 2003; Perona and Sa´nchez-Pe´rez, 2004) . Apart from the signaling pathways activated by oncogenic transformation in the tumor, it is important to know which other molecules are involved in the response to the drugs used in cancer treatment, and how such responses are modified by the genetic background of the tumor cells. Cisplatin is included in most protocols for the treatment of advanced NSCLC, but, to date, the patient's response to this drug is, often, far from optimum. We considered that sensitizing the cells to the therapeutic agent would be a way of obtaining a better response from the tumor to the drug, and also of combating any resistance to the drug by the tumor.
Constitutive expression of MKP1 in NSCLC has already been described by other authors (Lim et al., 2003) , finding an increase in mRNA levels of MKP1 in MKP1 controls sensitivity to cisplatin in NSCLC S Chattopadhyay et al NSCLC tumors compared to control tissue. A recent report (Vicent et al., 2004 ) also demonstrated elevated levels of nuclear MKP1 expression in NSCLC biopsies and derived cell lines. In agreement with this latter study, we found differences in sub-cellular distribution of MKP1: mainly cytoplasmic in normal tissue and nuclear in tumor tissue. As the preferred substrate of MKP1 is JNK and this is translocated to the nuclei following a stimulus (Sa´nchez-Pe´rez et al., 1998) , it appears reasonable to propose that a preferential distribution of MKP1 to this sub-cellular compartment would be to facilitate its access to the substrate. Furthermore, we found that expression of MKP1 was detected from very early stages in tumor development and maintained until later stages, indicating that it should be advantageous for tumor progression. 
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We studied the kinetic activation of the kinases involved in cisplatin responses in a cell line derived from NSCLC that constitutively expresses the MKP1 phosphatase. Although H-460 cells are sensitive to cisplatin, as shown by the IC 50 values, the kinetics for JNK and p38 activation are very late onset (around 9 h). As the kinetic for JNK activation in response to cisplatin depends very much on the dual-specific phosphatase MKP1/CL100, we modulated MKP1 levels in these cells by inhibiting expression of MKP1 by siRNA. Using this approach, we found that the sensitivity of H-460 cells to cisplatin increases by one order of magnitude, which indicated that this approach was valid for cells that overexpressed MKP1. In such a case, the activation of the JNK and p38 pathways is increased relative to control cells and, therefore, cisplatin-induced cell death is also increased.
MKP2 is a dual-specific phosphatase that has 60% homology at the amino-acid level and similar substrate specificity for MKP1. Also, it is overexpressed in H-460 cells. We did not observe any difference with respect to cell survival when MKP2 expression was knocked-down by siRNA in H-460 cells, confirming, thereby, that the effect of knocking-down the expression of MKP1 is very specific.
Ectopic expression of MKP1 is able to inhibit apoptosis induced by other types of stresses, such as UVC exposure (Liu et al., 1995) . MKP1 expression has been reported to be high in different types of tumors. For example, DU145, a hormone-refractory prostate cancer cell line, shows high levels of MKP1 (MagiGalluzzi et al., 1997; Srikanth et al., 1999) . Inhibition of MKP1 expression is able to sensitize DU145 cells to Fas ligand and TNF-a induced apoptosis (Srikanth et al., 1999) , as well as in renal cancer cells (Mizuno et al., 2004) . Overexpression of MKP1 in primary human ovarian carcinoma correlates with shorter progressionfree survival times (Denkert et al., 2002) and, finally, increases the expression of MKP1 and MKP2 correlated with low JNK activity in breast cancer (Wang et al., 2003) . Evidence presented recently demonstrated the MKP1 deficient MEFs are also more sensitive to apoptosis induction by anysomicin than parental cells, owing to a higher activation of JNK and p38 (Wu and Bennett, 2005) . All this evidence reported in the literature suggested to us that overexpression of MKP1 in human tumors protects cells from different types of stress and, therefore, was conducive to tumor growth. We confirmed this observation in the present study in NSCLC. It is not clear to us whether the subcellular distribution of MKP1 in the nuclei as well as in the cytoplasm in the tumor tissue of NSCLC patients is simply due to a concentration effect of overexpression or whether there are also differences in signaling that direct MKP1 to different sub-cellular distributions.
The strategy of inhibition of MKP1 expression in NSCLC cell lines by RNA interference and the increase in chemotherapy effectiveness was not only functional in the cell lines but also had long-term implications, as observed in the clonogenic survival assay and also in the tumors induced by the H-460MKP1siRNA cells. Surprisingly, tumors induced by H-460MKP1siRNA cells showed a slower kinetic of growth than the ones induced by control cells. This difference between in vitro and in vivo growth of the cell lines can be related to the greater ability of H-460 cells to withstand environmental conditions than control cells, or perhaps this reflects a reduction in tumorigenicity of these cells. Supporting this possibility is the report (Liao et al., 2003) that downregulation of MKP1 expression by antisense technology was able to reduce tumorogenicity in pancreatic cancer cells. Apart from the decrease in growth, H-460MKP1siRNA tumors were more responsive to cisplatin than control cells. As a consequence of inhibition of MKP1 expression, a greater than three-fold reduction in the increase in volume of tumor (non-vs cisplatin-treated transfected cells) is observed; the difference in the control cells was only two-fold. Of note was the observation that the volume of the H-460siRNA tumors increases only two-fold after 20 days of treatment and emphasizes the retardation of growth in these tumors.
Given the poor response of NSCLC to conventional chemotherapy, the results in the present report are highly encouraging, as they support the idea that MKP1 inhibition or inactivation is a good strategy both to inhibit tumor growth and to sensitize cancer cells to conventional chemotherapy, and this results in an important decrease in tumor size. Interestingly, MKP1 also plays an antiapoptotic role with new therapeutic agents, such as PS-341. Breast cancer cells overexpressing MKP1 are sensitized to PS341, by inhibition of MKP1 expression (Small et al., 2004) , reinforcing the idea that inhibition of MKP1 is an important target for tumor regression and induction of improvement in chemotherapy-dependant cellular response.
Materials and methods
H-460, H-23 and H1299 cell lines were purchased from the American Type Culture Collection (ATCC) and maintained in RPMI supplemented with 10% FBS. Antibodies used were anti-MKP1 (M18; Santa Cruz Biotechnologies, Santa Cruz, CA, USA), anti-pJNK (V7391; Promega, Madison, WI, USA), anti-c-myc (sc-789; Santa Cruz Biotechnologies), anti-JNK1 (C-17; Santa Cruz Biotechnologies), anti-P38 (C20; Santa Cruz Biotechnologies), anti-pP38 (9211S; Cell Signaling, Beverly, MA, USA) and anti-b-tubulin (T9026; Sigma, St Louis, MO, USA), anti-c-jun (H16; Santa Cruz Biotechnologies), anti-MKP2 (2518; Santa Cruz Biotechnologies) and anti-PARP (H-250; Santa Cruz Biotechnologies). ECL kit was from Amersham (Amersham, UK). Cisplatin and RO-31-8220 were purchased from Calbiochem. Puromycin and geneticin were from Sigma-Aldrich.
siRNA constructions and transfections pSuperRetro was from Oligoengine (Seattle, WA, USA). The MKP1 and MKP2 pSuperRetro-derived vectors (pSR) were constructed by using forward primer 5 0 -GATCCCCCGCCGG CCACATCGCCGGCTTCAAGAGAGCCGGCGATGTGG CCGGCGTTTTTGGAA-3 0 and reverse primer 5 0 -AGCTT TTCCAAAAACGCCGGCCACATCGCCGGCTCTCTTGA AGCCGGCGATGTGGCCGGCGGGG-3 0 for MKP1, and MKP1 controls sensitivity to cisplatin in NSCLC S Chattopadhyay et al forward primer 5 0 GATCCCCCGTGCGCTGTAACACCA TCTTCAAGAGAGATGGTGTTACAGCGCACGTTTTTG GAAA-3 0 and reverse primer 5 0 AGCTTTTCCAAAAACGTG CGCTGTAACACCATCTCTCTTGAAGATGGTGTTACA GCGCACGGGG-3 0 for MKP2. The primers were annealed and cloned into pSuperRetro cut with HindIII and BglII to generate pSRMKP1RNAi and pSRMKP2RNAi. Ampicillin-resistant colonies were selected and checked by sequencing using pSuperRetro vector sequence primers 5 0 ACCTCCTCGTTCGACGG-3 0 for direct and 5 0 TGTGAGGGACAGGGGAG-3 0 for reverse sequencing. PLXSN and pLXSN-CL100 have been described previously (Sa´nchez-Pe´rez et al., 2000) . pSG5MKP2 plasmid containing a myc-tagged epitope was kindly donated by Dr Stephen Keyse. For stable transfections, 1 mg of the each construct was transfected in a 60 mm plate. Transfections were carried out using Lipofectamine 2000. Cells were treated with 2.5 mg/ml of puromycin or geneticin during 24-48 h and kept for selection. Stable transfection was confirmed by Western blotting.
Cell extracts, Western blots and RT-PCR Whole-cell extracts were prepared essentially as described previously (Sa´nchez-Pe´rez et al., 1998) . Western blotting was performed using standard methods (Sa´nchez-Pe´rez et al., 1998) . For RT-PCR, total RNA was isolated from cells using Trizol (Life Technologies, Rockville, MD, USA) according to the manufacturer's instructions. For RT-PCR, single-strand cDNA was synthesized using a reverse MKP1 primer, 5 0 GCGCTCGTCCAGGAACACCACGGC 0 3, and PCR amplification was carried out with the direct primer, 5 0 CATGGAAGTGGGCACCCTGGACG 0 3 and the above-mentioned reverse primer. The reaction conditions were as follows: 1 Â (951C, 1 min), 25 Â (941C, 45 s, 601C 45 s and 721C, 30 s) and 1 Â (721C, 4 min). The products were analysed on a 1% agarose gel and stained with ethidium bromide.
Cell viability, growth kinetic and clonogenic assay determinations Cell viability was determined using a crystal violet staining method followed by colorimetric assay, as described previously (Sa´nchez-Pe´rez et al., 1998) . For the growth kinetic studies, cells were plated in triplicate at 1000 cells/well in a 24-well plate and allowed to grow in normal culture medium. Cells were fixed with glutaraldehyde at alternate days, stained by crystal violet and cell number determined. The increase in growth was calculated in relation to the cell number observed on day 1. For the clonogenic assay, cells were plated at a density of 10 000 cells/well, in triplicates in six-well plates. Cells were treated for 48 h with cisplatin 5 mg/ml. Then, the cells were washed and allowed to form colonies. The colony-forming capacity was calculated by fixing the cells with glutaraldehyde, and staining with crystal violet followed by colorimetric assay as mentioned above. Controls were untreated cells cultured in parallel and the percentage colony formation was calculated with respect to the number of colonies formed by the untreated cells. The colony-forming capacity of control cells corresponds to 100%.
Tumorigenicity
Tumors were induced on nu À /nu À mice by inoculating a million cells of H-460 wt and H-460siRNA cells per mice. After 14 days, cisplatin was administered at 5 mg/kg mouse body weight every alternate day for a total of five administrations. Tumor measurements were recorded from the 1st day of drug administration and tumor volume calculated as l Â w2 Â 0.52, where l is the length and w the width of the tumors. An average of four mice per treatment was used with two tumors on each in order to satisfy statistical constraints. All mice were housed under similar humane conditions in accordance with the regulations of the Spanish Government concerning experimental animal research.
Immunohistochemistry
Formalin-fixed and paraffin-embedded blocks from 32 surgical biopsies of NSCLC were selected to be analysed by immunohistochemistry. The blocks included, whenever possible, invasive carcinoma and surrounding non-tumor epithelium. Institutional approval to conduct the study was obtained.
Sections of 5 mm were cut from formalin-fixed, paraffinembedded tissue blocks from the aforementioned patients. Slides were de-paraffined and endogenous peroxidase activity was blocked by incubation in 3% H 2 O 2 in methanol for 10 min at room temperature (RT). Antigens were retrieved by incubation in EDTA for 45 min at 1551C. The primary polyclonal antibody (Santa Cruz Biotechnology) was diluted at 1:200 in 1% BSA in TBS. Tissue slides were incubated with the antibody for 1 h at RT. Slides were then rinsed in TBS and incubated with the peroxidase-based EnVisionTM kit (Dako Corporation, Carpinteria, CA, USA) for 30 min at RT. Afterwards, specimens were incubated with diaminobenzidine chromogenic substrate (Dako Corporation) for 5 min at RT. Sections were counterstained with hematoxylin, stepwise dehydrated through graded alcohols and cleared in xylene. As a control for nonspecific staining, three tumor tissues slides were stained with, and without, pre-adsorption of the primary antibody with a human control peptide (10 mg/ml; Santa Cruz Biotechnology). The evaluation of MKP1 immunostaining was scored by two expert surgical pathologists of the hospital. The tumors were scored according to the proportion of nuclei or cytoplasm stained within the tumor. In all cases, the cutoff point was dictated by the median values and used only for experimental correlation studies.
Inmunocytochemistry for MKP1 of cultured cells was performed in cells fixed with paraformahaldehyde. Cells were grown on coverslips and to 60% confluence, fixed and permeabalized with Triton X-100. Cells were stained with the MKP1 antibody and then with a secondary fluorescencelabeled antibody.
Statistical analysis
Statistical analysis was performed using the SPSS data analysis program v. 10.0. The test used was the w 2 with correction for 2 degrees of freedom and for expected sequences lower than 5.
